DeepMed Research

SWEDISH ORPHAN BIOVITRUM

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: $10.7B

Website: http://www.sobi.com/

Clinical Trials

Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

Phase 2

Terminated

Conditions: Graft Failure

Interventions: Drug: Emapalumab

First Posted Date: 2021-01-29

Last Posted Date: 2023-12-28

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 2

Registration Number: NCT04731298

Locations: 🇨🇦
CHU Sainte-Justine, Montréal, Quebec, Canada
🇮🇱
The Rambam Academic Hospital, Haifa, Israel
🇮🇱
Hadassah Hebrew University, Jerusalem, Israel

and more 2 locations

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

Phase 3

Completed

Conditions: Chronic Gout

Interventions: Drug: SEL-212 high-dose
Other: Placebo
Drug: SEL-212 low-dose

First Posted Date: 2020-10-22

Last Posted Date: 2024-02-20

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 153

Registration Number: NCT04596540

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Arthritis Center of North Georgia, LLC, Gainesville, Georgia, United States
🇺🇸
Carolina Research Center, Inc, Shelby, North Carolina, United States

and more 50 locations

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Phase 3

Completed

Conditions: Chronic Gout

Interventions: Drug: SEL-212 low-dose
Drug: SEL-212 high-dose
Other: Normal Saline

First Posted Date: 2020-08-14

Last Posted Date: 2024-02-20

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 112

Registration Number: NCT04513366

Locations: 🇺🇸
Clinical Research Of West Florida Incorporated, Clearwater, Florida, United States
🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸
Klein and Associates, M.D., P.A., Hagerstown, Maryland, United States

and more 36 locations

A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

Terminated

Conditions: Graft Failure

Interventions: Procedure: blood collection

First Posted Date: 2020-07-31

Last Posted Date: 2022-10-21

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 101

Registration Number: NCT04494061

Locations: 🇧🇪
Algemeen Ziekenhuis Delta - Campus Rumbeke, Roeselare, West-Vlaanderen, Belgium
🇫🇷
Hôpital Pontchaillou, Rennes cedex 9, Bretagne, France
🇫🇷
Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Rhône, France

and more 22 locations

Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.

Phase 2

Terminated

Conditions: SARS-CoV-2

Interventions: Biological: Anakinra
Biological: Emapalumab

First Posted Date: 2020-03-27

Last Posted Date: 2022-03-10

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 16

Registration Number: NCT04324021

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Regions hospital, Saint Paul, Minnesota, United States
🇺🇸
The Valley hospital, Ridgewood, New Jersey, United States

and more 9 locations

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: ELOCTA

First Posted Date: 2020-03-03

Last Posted Date: 2025-01-22

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 427

Registration Number: NCT04293523

Locations: 🇴🇲
The Royal Hospital, Muscat, Oman
🇨🇿
University Hospital Brno, Brno, Czechia
🇨🇿
University Hospital Ostrava, Ostrava, Czechia

and more 50 locations

Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination

Not Applicable

Completed

Conditions: Hemophilia A

Interventions: Procedure: Ultrasound, Haemophilia Joint Health Score

First Posted Date: 2019-10-21

Last Posted Date: 2024-07-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 88

Registration Number: NCT04133883

Locations: 🇫🇷
Swedish Orphan Biovitrum Reserach site, Paris, France
🇫🇷
Swedish Orphan Biovitrum Research Site, Tours, France
🇫🇷
Swedish Orphan Biovitrum Research site, Toulouse, France

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

Phase 2

Terminated

Conditions: Hemophagocytic Lymphohistiocytoses

Interventions: Drug: Emapalumab-Lzsg

First Posted Date: 2019-06-13

Last Posted Date: 2023-10-06

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 7

Registration Number: NCT03985423

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

Completed

Conditions: Hemophilia A With Inhibitor

Interventions: Other: rFVIIIFc

First Posted Date: 2019-05-15

Last Posted Date: 2024-07-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 44

Registration Number: NCT03951103

Locations: 🇨🇭
Swedish Orphan Biovitrum Research Site, Bern, Switzerland
🇸🇦
Swedish Orphan Biovitrum Research Site (a), Riyadh, Saudi Arabia
🇸🇦
Swedish Orphan Biovitrum Research Site (p), Riyadh, Saudi Arabia

Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Completed

Conditions: Still Disease, Juvenile Onset

Interventions: Drug: Anakinra

First Posted Date: 2019-04-30

Last Posted Date: 2019-11-14

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 306

Registration Number: NCT03932344

Locations: 🇮🇹
IRCCS Istituto G. Gaslini, Genova, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy